Overview Dividends

(NVO) Novo Nordisk - Ratings and Ratios

Exchange: NYSE • Country: Denmark • Currency: USD • Type: Common Stock • ISIN: US6701002056

Insulin, Obesity Medication, Hemophilia Drugs, Growth Hormone, Diabetes Pens

NVO EPS (Earnings per Share)

EPS Growth (3Y CAGR): 138.97%
EPS Trend (3Y Correlation): 87.5%

NVO Revenue

Revenue Growth (3Y CAGR): 17.52%
Revenue Trend (3Y Correlation): 92.4%

Risk via 10d forecast
Volatility	40.3%
Value at Risk 5%th	58.9%

Reward
Sharpe Ratio	-1.30
Alpha Jensen	-61.45

Character
Hurst Exponent	0.509
Beta	0.352

Drawdowns 3y
Max DD	68.50%
Mean DD	20.11%

Description: NVO Novo Nordisk September 24, 2025

Novo Nordisk A/S (NYSE:NVO) is a Denmark-based, globally-distributed pharmaceutical company that develops, manufactures, and markets medicines across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and other regions.

The firm operates two primary segments: (1) Diabetes & Obesity Care, which supplies insulin, GLP-1 agonists, and emerging cardiovascular and obesity therapies; and (2) Rare Disease, which focuses on treatments for rare blood and endocrine disorders as well as hormone-replacement products. Ancillary offerings include insulin and growth-hormone pens, injection needles, and digital tools such as smart insulin pens and the Dose Check dose-guidance app.

Strategic collaborations augment its pipeline: a UNICEF partnership targets childhood obesity, while a joint venture with Valo Health aims to discover novel cardiometabolic candidates. Novo Nordisk was founded in 1923 and remains headquartered in Bagsværd, Denmark.

Key recent metrics (FY 2023): revenue of DKK 141 billion (≈ US$ 20 billion), a 12 % YoY increase driven largely by growth in GLP-1 products; R&D spend of DKK 15 billion (≈ 2 % of sales), reflecting continued investment in next-generation obesity and rare-disease pipelines; and an operating margin of 31 %, well above the GICS Pharmaceuticals average of 22 %. The diabetes market’s secular tailwinds-rising global prevalence (≈ 537 million adults) and expanding indications for GLP-1 agents-support Novo Nordisk’s revenue outlook, while pricing pressure in mature insulin markets remains a risk factor.

For a deeper quantitative assessment of Novo Nordisk’s valuation metrics, the ValueRay platform offers a granular, data-driven view worth exploring.

NVO Stock Overview

Market Cap in USD	210,029m
Sub-Industry	Pharmaceuticals
IPO / Inception	1982-01-04
Return 12m vs S&P 500	-59.9%
Analyst Rating	3.50 of 5

NVO Dividends

Dividend Yield	3.43%
Yield on Cost 5y	5.40%
Yield CAGR 5y	21.92%
Payout Consistency	96.1%
Payout Ratio	7.2%

NVO Growth Ratios

CAGR	-3.11%
CAGR/Max DD Calmar Ratio	-0.05
CAGR/Mean DD Pain Ratio	-0.15
Current Volume	27531.8k
Average Volume	12172.2k

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (103.77b TTM) > 0 and > 6% of Revenue (6% = 18.94b TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -4.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -16.63% (prev -4.88%; Δ -11.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.24 (>3.0%) and CFO 123.78b > Net Income 103.77b (YES >=105%, WARN >=100%)

Net Debt (69.13b) to EBITDA (161.44b) ratio: 0.43 <= 3.0 (WARN <= 3.5)

Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.31% (target <= -2.0% for YES)

Gross Margin 82.05% (prev 84.66%; Δ -2.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 69.38% (prev 68.08%; Δ 1.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.03 (EBITDA TTM 161.44b / Interest Expense TTM 17.96b) >= 6 (WARN >= 3)

Altman Z'' 3.05

(A) -0.10 = (Total Current Assets 181.88b - Total Current Liabilities 234.36b) / Total Assets 512.29b

(B) 0.33 = Retained Earnings (Balance) 168.53b / Total Assets 512.29b

(D) 0.50 = Book Value of Equity 169.90b / Total Liabilities 342.39b

Total Rating: 3.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.16

1. Piotroski 6.0pt = 1.0

2. FCF Yield 4.40% = 2.20

3. FCF Margin 19.88% = 4.97

4. Debt/Equity 0.60 = 2.33

5. Debt/Ebitda 0.43 = 2.36

6. ROIC - WACC (= 37.31)% = 12.50

7. RoE 66.95% = 2.50

8. Rev. Trend 92.37% = 6.93

9. EPS Trend 87.53% = 4.38

What is the price of NVO shares?

As of November 12, 2025, the stock is trading at USD 49.15 with a total of 27,531,800 shares traded.
Over the past week, the price has changed by +1.87%, over one month by -14.52%, over three months by -0.33% and over the past year by -53.70%.

Is Novo Nordisk a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Novo Nordisk (NYSE:NVO) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 89.16 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NVO is around 41.44 USD . This means that NVO is currently overvalued and has a potential downside of -15.69%.

Is NVO a buy, sell or hold?

Novo Nordisk has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold NVO.

Strong Buy: 4
Buy: 1
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the NVO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	59.7	21.5%
Analysts Target Price	59.7	21.5%
ValueRay Target Price	45.6	-7.2%

NVO Fundamental Data Overview November 09, 2025

Market Cap DKK = 1357.81b (210.03b USD * 6.4649 USD.DKK)
P/E Trailing = 12.7242
P/E Forward = 14.0845
P/S = 0.6655
P/B = 9.8798
P/EG = 1.4816
Beta = 0.352
Revenue TTM = 315.60b DKK
EBIT TTM = 144.17b DKK
EBITDA TTM = 161.44b DKK
Long Term Debt = 84.25b DKK (from longTermDebt, last fiscal year)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1426.45b DKK (1357.81b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.03 (Ebit TTM 144.17b / Interest Expense TTM 17.96b)
FCF Yield = 4.40% (FCF TTM 62.74b / Enterprise Value 1426.45b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 2.78 (Enterprise Value 1426.45b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 113.03b (EBIT 144.17b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.43 (Net Debt 69.13b / EBITDA 161.44b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.26% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 60.26% (EBIT 144.17b / Capital Employed (Equity 155.00b + L.T.Debt 84.25b))
RoIC = 44.38% (NOPAT 113.03b / Invested Capital 254.70b)
WACC = 7.07% (E(1357.81b)/V(1459.03b) * Re(7.31%) + D(101.21b)/V(1459.03b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 7.31% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 78.90% ; FCFE base≈64.61b ; Y1≈67.41b ; Y5≈77.85b
Fair Price DCF = 405.7 (DCF Value 1366.55b / Shares Outstanding 3.37b; 5y FCF grow 4.61% → 3.0% )
EPS Correlation: 87.53 | EPS CAGR: 139.0% | SUE: 1.50 | # QB: 1
Revenue Correlation: 92.37 | Revenue CAGR: 17.52% | SUE: -0.03 | # QB: 0

Additional Sources for NVO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle